Online inquiry

IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3142MR)

This product GTTS-WQ3142MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets C3&C4 gene. The antibody can be applied in Cardiopulmonary bypass (CPB) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000064.4; NM_001002029.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 718; 721
UniProt ID P01024; P0C0L4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3142MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10080MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19TNF
GTTS-WQ4088MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ14145MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ11296MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-522
GTTS-WQ12982MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ773MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ11051MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ8762MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW